PROM1 and prostate carcinoma: Tumour cells expressing CD133 have been confirmed to be stem cells in human brain tumours, colon cancer, prostate cancer, liver cancer, melanoma, pancreatic cancer and other types of solid tumours (8,14–19), suggesting that CD133 may be a broad-spectrum marker of cancer stem cells (20).